Ventyx Biosciences Inc

NASDAQ:VTYX  
18.74
+0.82 (+4.58%)
Earnings Announcements

Ventyx Biosciences Reports Q1 2022 Results

Published: 05/12/2022 20:10 GMT
Ventyx Biosciences Inc (VTYX) - Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress.
Topline Phase 1 Data for Our Allosteric Tyk2 Inhibitor, Vtx958, Expected in Early Q3 2022.
Topline Phase 1 Data for Our Selective Nlrp3 Inhibitor, Vtx2735, Expected in Q2 2022.
Ventyx Biosciences - Believe Current Cash, Cash Equivalents & Marketable Securities Are Sufficient to Fund Planned Operations Into First Half of 2024.
Qtrly Loss per Share $0.45.
Q1 Earnings per Share View $-0.52 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.46

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.48

More details on our Analysts Page.